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Abstract
The phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) signaling axis has emerged as a novel target
for cancer therapy. Agents that inhibit PI3K, mTOR or both are currently under development. The mTOR allosteric inhibitor,
RAD001, and the PI3K/mTOR dual kinase inhibitor, BEZ235, are examples of these agents. We were interested in developing
strategies to enhance mTOR-targeted caner therapy. In this study, we found that BEZ235 alone effectively inhibited the
growth of rapamycin-resistant cancer cells. Interestingly, the combination of sub-optimal concentrations of RAD001 and
BEZ235 exerted synergistic inhibition of the growth of human lung cancer cells along with induction of apoptosis and G1
arrest. Furthermore, the combination was also more effective than either agent alone in inhibiting the growth of lung
cancer xenografts in mice. The combination showed enhanced effects on inhibiting mTOR signaling and reducing the
expression of c-Myc and cyclin D1. Taken together, our results suggest that the combination of RAD001 and BEZ235 is a
novel strategy for cancer therapy.
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Introduction
K-Ras, LKB1 and epidermal growth factor receptor (EGFR)
are frequently mutated in non-small cell lung cancer (NSCLC).
These mutations result in aberrant activation of the phosphoino-
sitide 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) signaling pathway [1,2,3]. Therefore, the PI3K/Akt/
mTOR signaling pathway has emerged as a promising therapeutic
target for NSCLC.
RAD001 (Everolimus) is a derivative of rapamycin and is
functionally similar to rapamycin as an allosteric inhibitor of
mTOR. In patients with advanced renal cell cancer previously
treated with VEGF targeted agents, RAD001 improves progres-
sion-free survival and has therefore been approved by the US
Food and Drug Administration for this indication [4]. It has also
been found to improve progression-free survival in patients with
neuroendcorine cancers of the pancreas. In many other solid
organ malignancies, RAD001 and other rapamycin analogues
(rapalogs) the rapalogs exert modest anti-cancer effects, that
though promising, are not sufficient to warrant monotherapy with
these agents [5].
Recent efforts to improve the efficacy of the rapalogs have
focused on developing novel combination strategies. NVP-
BEZ235 (BEZ235) is a novel and orally administered dual PI3K
and mTOR kinase inhibitor. This compound is a potent,
reversible inhibitor of both class I PI3K and mTOR kinase
catalytic activity by competing at their ATP-binding site [6].
BEZ235 is currently under evaluation in phase I/II clinical trials.
In preclinical studies, BEZ235 induces striking anti-proliferative
effects both in transgenic mice with oncogenic K-Ras-induced
NSCLC and in NSCLC cell lines expressing oncogenic K-Ras.
Moreover, it effectively sensitizes NSCLC cell lines expressing
oncogenic K-Ras to the pro-apoptotic effects of ionizing radiation
both in vitro and in vivo [7]. When BEZ235 was combined with a
MEK inhibitor, marked synergy was achieved in shrinking K-Ras
mutant murine lung cancers [8].
Like rapamycin, RAD001 causes Akt activation in human
cancer cells including NSCLC cells while inhibiting the mTOR
signaling [9]. We recently reported on the enhanced efficacy of the
combination of RAD001 with a PI3K inhibitor on the growth of
NSCLC cells both in vitro and in vivo [9]. Interestingly, BEZ235
could overcome rapamycin resistance as it effectively inhibited the
growth of rapamycin- or RAD001-resistant NSCLC cells.
Therefore we evaluated the effects of the combination of
RAD001 and BEZ235 on the growth of NSCLC cells and found
that the combination was more effective than either agent alone in
inhibiting the growth of NSCLC cells both in vitro and in vivo. This
report will primarily document our research findings in this
regard.
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20899Materials and Methods
Reagent
RAD001 and BEZ235 were supplied by Novartis Pharmaceu-
ticals Corporation (East Hanover, NJ), dissolved in DMSO and
stored at 280uC. Rabbit polyclonal anti-actin antibody was
purchased from Sigma Chemical Co. (St. Louis, MO). Antibodies
against Akt, p-Akt (S473), p-S6 (S235/S236), S6, p-4EBP1 (S65) p-
4EBP1 (Thr37/46), 4EBP1, eIF4G, eIF4E, and poly(ADP-
ribose)polymerase (PARP), respectively, were purchased from Cell
Signaling Technology, Inc. (Beverly, MA). Goat polyclonal
mTOR (FRAP; N-19) and mouse monoclonal c-Myc (9E10)
antibodies were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA), respectively. Rabbit polyclonal Rictor (BL2178)
antibody was purchased from Bethyl Laboratories, Inc. (Mon-
tgomery, TX). Mouse monoclonal cyclin D1 antibody was
purchased from Dako (Carpinteria, CA).
Cell Lines and Cell Culture
The human NSCLC cell lines A549, H460 and H157 were
described previously [10]. HCC827 was purchased from the
American Type Culture Collection ATCC (Manassas, VA). Rapa-
mycin-resistant A549 cell line (A549-RR) was established previously
[9]. These cell lines were grown in monolayer culture in RPMI 1640
medium supplemented with 5% fetal bovine serum (FBS) at 37uCi na
humidified atmosphere consisting of 5% CO2 and 95% air.
Growth Inhibition Assay
Cells were cultured in 96-well cell culture plates and treated the
next day with the agents indicated. Viable cell number was
estimated using the sulforhodamine B (SRB) assay, as previously
described [10]. Combination index (CI) for drug interaction (e.g.,
synergy) was calculated using the CompuSyn software (Combo-
Syn, Inc.; Paramus, NJ).
Colony Formation Assay
The effects of the given drugs on colony formation on plates
were measured as previously described [11].
Detection of Apoptosis
Apoptosis was evaluated by Annexin V staining using Annexin
V-PE apoptosis detection kit purchased from BD Biosciences (San
Jose, CA) according to the manufacturer’s instructions.
Western Blot Analysis
Preparation of whole cell protein lysates and Western blot
analysis were described previously [12,13].
m
7GTP Pull-down for Analysis of eIF4F Complex
Formation
eIF4F complex in cell extracts was detected using affinity
chromatography m
7GTP-Sepharose as described previously [14].
Detection of mTOR complexes (mTORCs)
mTORCs including mTORC1 and mTORC2 were immuno-
precipitated with goat polyclonal mTOR (FRAP; N-19) antibody
and followed with Western blotting to detect mTOR, raptor and
rictor, respectively, as described previously [9].
Lung Cancer Xenografts and Treatments
Animal experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) of Emory University. The
protocol number is 222-2008. Five- to 6-week old female athymic
(nu/nu) mice were ordered from Taconic (Hudson, NY) and
housed under pathogen-free conditions in microisolator cages with
laboratory chow and water ad libitum. A549 cells at 5610
6 in
serum-free medium were injected s.c. into the flank region of nude
mice. When tumors reached a size of approximately 100 mm
3, the
mice were randomized into four groups (n=6/group) according to
tumor volumes and body weights for the following treatments:
vehicle control, BEZ235 (20 mg/kg/day, og), RAD001 (3 mg/kg/
day; og), and their combination. Tumor volumes were measured
using caliper measurements once every two days and calculated
with the formula V=p(length6width
2)/6.
Statistic Analysis
The statistical significance of differences between two groups or
among multiple groups was analyzed with two-sided unpaired
Student’s t tests (for equal variances) or with Welch’s corrected t
test (unequal variances) or one-way analysis of variance (ANOVA)
by use of Graphpad InStat 3 software. Results were considered to
be statistically significant at P,0.05.
Results
BEZ235 Effectively Inhibits the Growth of Rapamycin-
resistant NSCLC Cells
In a prior study, we established a rapamycin-resistant cell line
(i.e., A549-RR). This cell line is also resistant to RAD001 [9]. We
anticipated that this cell line would be, at least in part, resistant to
BEZ235 since it is a PI3K and mTOR dual inhibitor. Unexpect-
edly, BEZ235 demonstrated potent inhibition of the growth of
A549-RR cells (Fig. 1A). Moreover, BEZ235 also induced apoptosis
in A549-RR cells (Fig. 1B). In fact, the induction of apoptosis and
growth inhibition with BEZ235 was slightly more effective in A549-
RR cell than in the parent A549 cells (Fig. 1). Thus, rapamycin-
resistant cells do not show cross-resistance to BEZ235.
The Combination of RAD001 and BEZ235 Synergistically
Inhibits the Growth of NSCLC Cells along with Induction
of Apoptosis and G1 arrest
We previously demonstrated that the combination of rapamycin
orRAD001withthe PI3KinhibitorLY294002resulted inenhanced
growth-inhibitory effects against NSCLC cells both in vitro and in vivo
[9,15]. We have now studied whether the combination of BEZ235
and RAD001 exerts augmented anti-cancer activity inNSCLC cells.
Unexpectedly, we found that the combination of low concentrations
of BEZ235 and RAD001 was much more potent than each single
agent in inhibiting the growth of several NSCLC cell lines (e.g.,
A549, H460, H157 and HCC827). The CIs for most combinations
were ,1 (Fig. 2A, right panels), indicating synergistic effects on
inhibiting the growth of NSCLC cells. In agreement, the
combination of BEZ235 and RAD001 was significantly more potent
than each single agent in inducing apoptosis (Fig. 2B) and G1 arrest
(Fig. 2C) (P,0.001). Thus, enhanced induction of both apoptosis
and cell cycle arrest contributes to augmented growth-inhibitory
effects induced by the combination.
The Combination of RAD001 and BEZ235 Effectively
Inhibits the Formation and Growth of NSCLC Cell
Colonies
We further determined the long-term effects of the combination
of RAD001 and BEZ235 on the growth of NSCLC cells in a colony
formation assay. This assay allows us to repeat the treatments for a
longtime(e.g., 12 days). RAD001 at a dose of 1 nM and BEZ235at
5 nM alone had minimal effect on suppression of colony formation
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colony formation (e.g., A549) or drastically reduced the colony
numbers (e.g., H460 and H157) (Fig. 3). Thus, it is clear that the
combination is much more effective than either single agent in
inhibiting the colony formation and growth of NSCLC cells
(P,0.001). We also compared the effect of sequence of adminis-
tration of the two agents on colony formation of NSCLC cells.
Under the same experimental conditions described above, sequen-
tial treatments with RAD001 first followed by BEZ235 treatment
(RAD001RBEZ235) or BEZ235 first followed by RAD001
treatment (BEZ235RRAD001) showed effects comparable to each
alone with minimal suppression of the growth of NSCLC cell
colonies. The concurrent combination of RAD001 and BEZ235
was much more potent than either sequential treatment in
inhibiting the formation and growth of NSCLC colonies
(P,0.001) (Fig. 2). Therefore, concurrent administration of
RAD001 and BEZ235 is clearly superior to sequential treatments
in inhibiting the growth of NSCLC cell colonies.
We further compared the effects of the combination of RAD001
and LY294002 with sequential treatments on colony formation of
NSCLC cells. Consistently, the concurrent combination treat-
ment, but not the sequential treatment either with RAD001 first
followed by LY294002 or with LY294002 followed by RAD001,
generated augmented effects on inhibiting the colony formation of
NSCLC cells (Fig. S1).
The Combination of RAD001 and BEZ235 Exerts
Augmented Activity against the Growth of NSCLC
Xenografts in Nude Mice
Because of the promising growth-inhibitory effects of the
RAD001 and BEZ235 combination in NSCLC cells in vitro,w e
then validated the efficacy of the combination against the growth
of NSCLC tumors in mice. Both RAD001 and BEZ235 partially,
but significantly, inhibited the growth of A549 xenografts
(P,0.01); however the combination of RAD001 and BEZ235
was significantly more potent than each single agent in inhibiting
the growth of the xenografts as measured by both tumor sizes and
weights (P,0.01) (Figs. 4A and 4B). These in vivo data further
demonstrate that the combination of RAD001 and BEZ235
displays augmented anticancer activity. We observed a higher
degree of weight loss in mice treated with the combination (up to
19% of control mice) especially during the early treatment period.
The weight difference at the end of the experiment improved to
only 13% of control (Fig. 4C), suggesting possible adaptation and
better tolerance of the combination treatment,
The Combination of RAD001 and BEZ235 Exerts
Enhanced Effects on Suppression of the mTOR signaling
and Downregulation of c-Myc and Cyclin D1
To gain insight into the mechanisms by which the combination
of RAD001 and BEZ235 exert enhanced anticancer activity, we
analyzed the effects of the combination on mTOR signaling and
on the expression of its regulated proteins in comparison with
either agent alone. At the tested doses, BEZ235 had a minimal
effect on reduced p-S6 levels, but no effect on the levels of p-
4EBP1 (both S65 and T37/46), c-Myc and cyclin D1. In fact, we
observed increased levels of 4EBP1 (T37/46) (in both A549 and
H157) and c-Myc (e.g., in H157). RAD001 at 2 nM strongly
inhibited S6 and 4EBP1 (S65) phosphorylation, but did not reduce
the levels of p-4EBP1 (T37/46), c-Myc and Cyclin D1. Similar to
BEZ235, RAD001 also increased the levels of p-4EBP1 (T37/46)
and c-Myc in both A549 and H157 cells. However the
combination of RAD001 and BEZ235 either abrogated the
increase in p-4EBP1 (T37/46) (e.g., in A549 cells) induced by the
single agent or exerted enhanced effect on reducing p-4EBP1
(T37/46) levels (e.g., in H157 cells). Importantly, the combination
of RAD001 and BEZ235 had augmented effects on decreasing the
levels of c-Myc and cyclin D1 in both A549 and H157 cells in
comparison with each single agent alone (Fig. 5).
RAD001 increased Akt phosphorylation in both A549 and
H157 cell lines as we previously reported [9]. Interestingly, at low
doses, BEZ235 also increased p-Akt levels. The presence of
BEZ235 at the tested dose ranges either weakly reduced the levels
of p-Akt induced by RAD001 (e.g., in A549 cells) or did not affect
Figure 1. BEZ235 is effective in inhibiting the growth (A) and
inducing apoptosis (B) of rapamycin-resistant cells. A, The
indicated cell lines were seeded in 96-well plates and then treated with
different concentrations of BEZ235 as indicated on the second day.
After 3 days, the cell numbers were estimated using SRB assay. Points,
means of four replicate determinations; bars, 6 SD. B, The indicated cell
lines were plated in 6-well plates and then treated next day with
different concentrations of BEZ235 as indicated. After 24 and 72 h, the
cells were harvested and subjected to detection of apoptosis using
Annexin V staining. Columns, means of duplicate determinations; bars,
6 SD.
doi:10.1371/journal.pone.0020899.g001
RAD001 and BEZ235 Combination against Lung Cancer
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20899RAD001-induced increase in p-Akt (e.g., in H157 cells) (Fig. 5).
Thus, it seems that the RAD001 and BEZ235 combination can
display enhanced effects on suppressing the mTOR signaling and
the expression of its regulated proteins with limited or no
inhibitory effects on Akt phophorylation.
The Combination of RAD001 and BEZ235 Exerts Enhanced
Effects on Suppressing eIF4F Assembly
Since mTOR signaling is known to positively regulate cap-
dependent translation initiation, we further analyzed the effects of
Figure 2. The combination of BEZ235 and RAD001 synergistically inhibits cell growth (A) and induces apoptosis (B) and cell cycle
arrest (C) in NSCLC cells. A, the indicated cell lines were seeded in 96-well plates and then treated next day with different concentrations of
BEZ235 (BEZ), RAD001 (RAD) and their respective combinations as indicated. After 3 days, the cell numbers were estimated using the SRB assay and
CIs were calculated with CompuSyn software (right panels). Points, means of four replicate determinations; bars, 6 SD. B and C, The indicated cell
lines were seeded in 6-well plates and then treated with 10 nM BEZ235 alone, 2 nM RAD001 alone, and their combination. After 48 h, the cells were
harvested for detection of apoptosis using Annexin V staining (A) and for cell cycle analysis with a flow cytometry (C). Columns, means of duplicate
determinations; Bars, 6 SD. *, P,0.05, ** P,0.01, and ***, P,0.001 compared with DMSO control; ###, P,0.001 compared with RAD001 or BEZ235
alone.
doi:10.1371/journal.pone.0020899.g002
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and eIF4G (e.g., eIF4F assembly) with the m
7GTP-Sepharose pull
down assay. As presented in Fig. 5B, RAD0001 and BEZ235 alone
reduced the amounts of eIF4G that interacted with eIF4E.
However, the combination of RAD001 and BEZ235 was much
more effective that either agent alone in decreasing the amounts of
eIF4G binding to eIF4E. Theses results clearly indicate that the
combination of RAD001 and BEZ235 exerts enhanced effects on
suppressing the cap binding of eIF4E and eIF4G or eIF4F
assembly.
The Combination of RAD001 and BEZ235 Does not
Exhibit Enhanced Effects on Inhibiting the Assembly of
mTORCs
It is known that the assembly or association of the mTOR with
its partners (e.g., raptor and rictor) is essential for distinct enzyme
activities and biological functions. RAD001, like rapamycin,
suppresses mTOR signaling by inhibiting the assembly of the
mTORCs [16]. Thus, we further determined whether the
combination of RAD001 and BEZ235 exerted enhanced
inhibitory effects on the assembly of the mTORCs including
mTORC1 (mTOR/raptor) and mTORC2 (mTOR/rictor). To
this end, we did immunoprecipitation (IP) with anti-mTOR
antibody to pull down both mTORC1 and mTORC2 and then
followed with Western blotting to detect raptor and rictor in the
immunoprecipitates. As presented in Fig. 6, BEZ235 had
minimal effects on reducing the levels of raptor and rictor in
the immunoprecipitates, whereas RAD001 substantially reduced
the levels of both raptor and rictor pulled down by mTOR
antibody. The combination of RAD001 and BEZ235 had similar
potency to RAD001 alone in reduction of the levels of raptor and
rictor in the immunoprecipitates, indicating that the combination
does not exhibit enhanced effects on inhibiting the assembly of
mTORC1 and mTORC2.
Discussion
Development of rapamycin resistance is a critical issue in the
treatment of cancer with rapamycin and its analogues [17].
Figure 3. The concurrent combination of BEZ235 and RAD001 effectively inhibits colony formation ands growth of NSCLC cell. The
indicated cell lines at a density of approximately 200 cells/well were seeded in 24-well plates. On the second day, the cells were treated with 1 nM
RAD001 (RAD), 5 nM BEZ235 (BEZ) or their concurrent combinations (RAD+BEZ). The cells were also treated with 1 nM RAD001 for 6 days followed
with 5 nM BEZ235 for another 6 days (RADRBEZ) or with 5 nM BEZ for 6 days followed with 1 nM RAD001 for another 6 days (BEZRRAD). After 12
days, the plates were stained for the formation of cell colonies with crystal violet dye. The picture of the colonies was then taken using a digital
camera (A) and the colony numbers were counted (B). ***, P,0.001 compared with DMSO control; ###, P,0.001 compared with all other
treatments.
doi:10.1371/journal.pone.0020899.g003
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study demonstrated that BEZ235 inhibited the growth of
rapamycin-resistant cells and induced apoptosis as effectively as
it did in the matched parent cells. In fact, rapamycin-resistant cells
were slightly more sensitive than their parental cells to BEZ235
(Fig. 1). These data suggest that rapamycin-resistant cells are not
cross-resistant to BEZ235. Since this cell line had been shown to
be fully resistant to RAD001, our findings suggest that BEZ235
inhibits the growth of cancer cells through different mechanisms
from those that mediate the actions of rapalogs. It will be
interesting to know if BEZ235 possess additional mechanism
beyond dual inhibition of PI3K and BEZ235. Beside, our data also
imply that BEZ235 can be used to overcome rapamycin resistance.
Although BEZ235 inhibits both PI3K and mTOR, in
combination with RAD001, it exerts synergistic effects in
inhibiting the growth of a panel of NSCLC cells as demonstrated
in a 3-day monolayer culture (with the SRB assay) and in a long-
term 12 days colony formation assay (Figs. 2 and 3). This synergy
is likely due to enhanced effects on induction of cell cycle G1 arrest
and apoptosis (Fig. 2). In agreement, the combination of RAD001
and BEZ235 was significantly more effective than either agent in
inhibiting the growth of NSCLC xenografts in nude mice (Fig. 4).
In the animal study, we noted that the combination initially caused
significant loss of body weight (up to 19% of control); however, at
the end of the experiment, mice receiving the combination
treatment seemed to recover some of the weight loss (13% of
control). This suggests that the mice can adapt and eventually
tolerate the treatment with the combination of RAD001 and
BEZ235. Nonetheless, we should aware potential enhanced
adverse effects caused by the combination while the combination
shows promising synergistic anticancer activity.
Treatment schedules may impact the final outcome of the given
combinational therapy. In this study, we found that the sequential
treatments with RAD001 followed by BEZ235 or with BEZ235
followed by RAD001 minimally inhibited the growth of NSCLC
colonies; in contrast, the concurrent treatment of RAD001 and
BEZ235 substantially inhibited growth of NSCLC colonies or
eliminated the colony formation (Fig. 3). This is also true for the
combination of rapamycin and LY294002 (Fig. S1). Our data
suggests that the concurrent combination of RAD001 and
BEZ235 may be optimal for further development of this
combination.
The IC50s (concentrations of inhibiting 50% cell growth) of
BEZ235 in human NSCLC cells range from 10 nM to 100 nM
(our unpublished data). In our combination experiments, we
typically used low dose ranges of BEZ235 (e.g., 1–10 nM). At these
doses, BEZ235 had a weak inhibitory effect on p-S6 phosphor-
ylation but did not modulate p-4EBP1 phosphorylation or the
levels of c-Myc and cyclin D1. At a dose of 2 nM, RAD001
effectively inhibited the phosphorylation of S6 and 4EBP1 (S65),
but did not suppress 4EBP1 phosphorylation (T37/46) and c-Myc
and cyclin D1 expression. However, the combination of RAD001
and BEZ235 effectively inhibited p-4EBP1 phosphorylation (at
T37/46) and reduced the levels of c-Myc and cyclin D1 (Fig. 5A).
Moreover, we showed that the combination of RAD001 and
BEZ235 was much more potent than either single agent in
inhibiting the cap binding of eIF4E and eIF4E or eIF4F assembly
(Fig. 5B), implying that the combination exerts enhanced
inhibitory effect on cap-dependent initiation. Since c-Myc and
cyclin D1 are known to be regulated by the mTOR signaling
through cap-dependent protein translation [18], our data indicate
that the combination of RAD001 and BEZ235 exerts enhanced
effect on inhibiting the mTOR signaling and the expression of its
regulated oncogenic proteins (e.g., c-Myc and cyclin D1). This
Figure 4. The combination of BEZ235 and RAD001 is signifi-
cantly more effective than each single agent in suppressing the
growth of NSCLC xenografts. A549 xenografts were treated (once a
day) with vehicle control, RAD001 (3 mg/kg, og), BEZ235 (20 mg/kg, og)
and their combination (BEZ+RAD) starting on the same day after
grouping. Tumor sizes (A) and body weight (C) were measured once
every two days. After 14 days, the mice were sacrificed and the tumors
were removed and weighed (B). Each measurement is a mean 6 SD
(n=6). The numbers in C represent body weight loss in the
combination group compared with control group. * P,0.05 compared
with vehicle control; ** P,0.01 compared with vehicle control; ***
P,0.001 compared with vehicle control;
## P,0.01 compared with
RAD001 or with BEZ235.
doi:10.1371/journal.pone.0020899.g004
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of NSCLC cells in vitro and in vivo by the combination of RAD001
and BEZ235.
In this study, RAD001 increased Akt phosphorylation in both in
A549 and H157 cells; this is in agreement with our previous
reports [9]. At the concentrations tested (e.g., 1–10 nM), BEZ235
increased p-Akt levels as well. This observation is consistent with a
previous report, in which BEZ235 was shown to increase Akt
phosphorylation at low doses (e.g., 10 nM) [19]. It had been
previously shown that higher concentrations of BEZ235 are
needed (e.g., .100 nM) to inhibit Akt compared with that (e.g.,
.10 nM) required for inhibiting S6 phosphorylation [19]. Thus, it
appears that BEZ235 primarily possesses mTOR-inhibitory
activity at the low concentrations ranges. Accordingly, it is
understandable that BEZ235 at low concentration ranges
increases Akt phosphorylation as would be expected of a rapalog
[9,15]. Interestingly, the combination of RAD001 and BEZ235
did not reduce p-Akt levels, which were as high as those in cells
treated with RAD001 or BEZ235 alone (Fig. 5). Given that the
combination of RAD001 and BEZ235 effectively inhibits the
growth of NSCLC cells as discussed above, it appears that the
combination of RAD001 and BEZ235 can exert enhanced
anticancer activity with elevated levels of p-Akt.
mTOR exerts its critical roles in promoting cell cycle
progression and cell proliferation primarily through interactions
with other proteins such as raptor (forming mTORC1) and rictor
(forming mTORC2) [18,20]. mTORC2 is generally thought to be
insensitive to rapalogs [18]. However, prolonged treatment with
these mTOR inhibitors disrupts the assembly of the mTORC2 as
demonstrated by us [9] and others [21]. In this study, after a 24 h
treatment, RAD001, but not BEZ235, effectively inhibit the
assembly or activity of both mTORC1 and mTORC2. The
combination of RAD001 and BEZ235 did not further reduce the
levels of raptor and rictor in the immunoprecipitates (Fig. 6),
demonstrating that the combination does not display enhanced
effects on inhibiting the assembly of mTORCs. Based on these
observations, we speculate that the enhanced effects on suppres-
sion of the mTOR signaling by the combination is likely due to
their distinctive effects on inhibiting the mTORC assembly and
mTOR kinase activity. It is generally believe that a synergy is
achieved through a corporation of two drugs functioning via
Figure 5. Effects of BEZ235 and RAD001 combination on the mTOR signaling (A), on the expression of mTOR-regulated proteins (A)
and on the assembly of eIF4F complex (B). A, The indicated cell lines were plated in 10 cm-diameter cell culture dishes and treated next day
with the given concentrations of BEZ-235 in the absence and presence of RAD001 for 24 h. The cells were then harvested for preparation of whole-
cell protein lysates and subsequent Western blot analysis to detect the indicated proteins. B, The indicated cell lines were treated with 2 nM RAD001,
10 nM BEZ235 or their combination. After 24 h, the cells were harvested for preparation of whole-cell protein lysates and subsequent m
7GTP pull-
down assay followed with Western blot analysis to detect the given proteins.
doi:10.1371/journal.pone.0020899.g005
Figure 6. The combination of RAD001 and BEZ235 does not
enhance disruption of mTORC assembly. A549 cells were treated
with 2 nM RAD001, 10 nM BEZ235 or their combination. After 24 h, the
cells were harvested for preparation of whole-cell protein lysates and
subsequent IP-Western blotting.
doi:10.1371/journal.pone.0020899.g006
RAD001 and BEZ235 Combination against Lung Cancer
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of the rapamycin-resistant cells, it is also possible that the synergy
between RAD001 and BEZ235 against the growth of lung cancer
cells occurs through an unknown mechanism of BEZ235, which
needs further investigation.
In summary, the current study has demonstrated that the
combination of RAD001 and the PI3K/mTOR inhibitor BEZ235
exhibits synergistic inhibition on the growth of NSCLC cells in vitro
and in vivo and thus represents a novel strategy to enhance the
efficacy of mTOR-targeted cancer therapy. Our findings provide
the rationale to evaluate this combination in clinical trials for
patients with rapalog-sensitive and refractory malignancies.
Supporting Information
Figure S1 Concurrent combination of rapamycin and
LY294002 is more effective than sequential treatments
in inhibiting the formation and growth of NSCLC
colonies. The indicated cell lines at a density of approximately
200 cells/well were seeded in 24-well plates. On the second day,
cells were treated with 1 nM rapamycin (Rap) alone, 5 nM
LY294002 (LY) alone, concurrent combination of rapamycin and
LY294002 (Rap+LY), rapamycin for 3 days and then switched to
LY294002 treatment (RapRLY), LY294002 for 3 days and then
switched to rapamycin treatment (LYRRap). The same cycles of
the treatments were repeated every 3 days. After 12 days, the
plates were stained for the formation of cell colonies with crystal
violet dye. The picture of the colonies was then taken using a
digital camera (A) and the colonies were counted (B).
(PDF)
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